JP Morgan Upgrades Zhihu to Neutral, Lowers Price Target to $1.5
JP Morgan analyst Alex Yao upgrades Zhihu (NYSE:ZH) from Underweight to Neutral and lowers the price target from $1.8 to $1.5.
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 807 companies reached new 52-week lows.
55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
24 Stocks Moving in Friday’s Pre-Market Session
Gainers
Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 35% to $3.47 in pre-market trading. Vinco Ventures set record date as May 18, 2022 For dividend of shares related to Cryptyde deal. The dividend is expected to be distributed on May 27, 2022.
11 Communication Services Stocks Moving In Wednesday’s After-Market Session
Gainers
Chicken Soup for the Soul (NASDAQ:CSSE) shares rose 4.1% to $8.51 during Wednesday's after-market session. The company's market cap stands at $130.7 million.
Zhihu in Quest to Be First Internet Firm with U.S., Hong Kong Primary Listings
Key takeaways:
Zhihu will make a second primary listing in Hong Kong alongside its current U.S. listing, aiming to ease U.S. regulatory pressure and reach more Chinese investors
Lukewarm interest in the new Hong Kong offering suggests investors are concerned about the company’s growing losses
By Jony Ho
66 Biggest Movers From Yesterday
Gainers
JX Luxventure Limited (NASDAQ: LLL) shares jumped 119.5% to settle at $4.39 on Tuesday after the company announced it signed a $60 million sales agreement.
42 Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Forge Global Holdings Inc. (NYSE: FRGE) shares jumped 67.7% to $16.95. True Global Ventures’ portfolio company Forge Global Holdings completed its business combination with Motive Capital Corp on the 22nd of March, 2022.
75 Biggest Movers From Yesterday
Gainers
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) shares jumped 299.4% to close at $6.23 on Monday as the company received clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.